Small molecule · Agonist of 5-HT1D receptor (HTR1D) · developed by Bausch
ApprovedFDA, Apr 1946
1Registered trials
What is Dihydroergotamine?
Dihydroergotamine is an ergotamine derivative that binds with high affinity to 5-HT1D receptors and acts as an agonist at them. It is used in the acute treatment of migraine, and one label also covers acute cluster headache.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.